406 related articles for article (PubMed ID: 33040166)
1. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
Chen J; Kuang S; Zhang Y; Tang W; Xie S; Zhang L; Rong D; He B; Deng Y; Xiao Y; Shi W; Fowler K; Wang J; Sirlin CB
Abdom Radiol (NY); 2021 Apr; 46(4):1530-1542. PubMed ID: 33040166
[TBL] [Abstract][Full Text] [Related]
2. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
[No Abstract] [Full Text] [Related]
3. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
[TBL] [Abstract][Full Text] [Related]
4. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
[No Abstract] [Full Text] [Related]
6. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
[TBL] [Abstract][Full Text] [Related]
7. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
Ghadimi M; Birnbaum J; Kamel IR; Sirlin CB; Chernyak V
Eur Radiol; 2022 May; 32(5):3327-3333. PubMed ID: 34807269
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
[TBL] [Abstract][Full Text] [Related]
9. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
[TBL] [Abstract][Full Text] [Related]
11. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS.
Cha DI; Choi GS; Kim YK; Kim JM; Kang TW; Song KD; Ahn SH
Eur Radiol; 2020 Jul; 30(7):3723-3734. PubMed ID: 32128620
[TBL] [Abstract][Full Text] [Related]
12. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
13. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
[TBL] [Abstract][Full Text] [Related]
14. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
[TBL] [Abstract][Full Text] [Related]
15. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
[TBL] [Abstract][Full Text] [Related]
16. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
[TBL] [Abstract][Full Text] [Related]
17. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
[TBL] [Abstract][Full Text] [Related]
18. Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma.
Cunha GM; Hasenstab KA; Delgado T; Ichikawa S; Lee MH; Dautt Medina PM; Kim SJ; Lee YH; Kwon H; Sirlin CB; Fowler KJ
Eur Radiol; 2021 Oct; 31(10):7594-7604. PubMed ID: 33876298
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]